This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Galapagos has already successfully discovered and validated novel targets in these bone and joint diseases, as well as in its asthma and Alzheimer’s disease programs….
The SilenceSelectTM collection is offered by Galádeno, Galapagos’ genomics services unit. The adenoviral collection contains siRNA knock-down sequences targeting over 4,000 human drugable transcripts, where…
About Galapagos Genomics NVGalapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer’s disease and asthma. Proprietary targets and…
Under the terms of the agreement, Galádeno (Galapagos’ wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect (TM) and FLeXSelect…
“We are excited that we have successfully delivered on our commitments in our osteoporosis program with Wyeth. The selection of these targets is a critical…
Mechelen, Belgium, September 22nd, 2004 – Galapagos Genomics NV, Europe’s leading target discovery company, announced today that it has created a new business unit for…
Mechelen, Belgium, June 7th, 2004 — Galapagos Genomics NV, Europe’s leading target discovery company, announced today that it has identified, validated and filed patent applications…
Galapagos will build a number of Alzheimer’s Disease relevant assays using neuronal cells and will use these in combination with its adenoviral based target discovery…
Mechelen, Belgium, December 16, 2003 – Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the Companies will collaborate…
Mechelen, Belgium, November 13, 2003 –Galapagos Genomics today announced that it has entered into a discovery alliance in the field of osteoporosis with Wyeth Pharmaceuticals,…